Viking Therapeutics, Inc. reported an insider ownership change for Hubert C. Chen in a Form 4 filed on June 3, 2026, covering a transaction date of June 1, 2026. The filing concerns derivative securities beneficially owned by Chen, which appear to involve a stock option award. The only substantive transaction detail provided in the document is the vesting schedule for the option. According to the explanatory footnote, 25% of the shares subject to the option vested immediately on the grant date, and an additional 25% will vest on each one-year anniversary of the grant date over the following three years. That structure indicates a four-year vesting schedule with one-quarter vesting upfront and the remainder vesting annually. The excerpt does not disclose the number of shares underlying the option, the exercise price, expiration date, transaction code, or Chen’s beneficial ownership after the transaction. It also does not show any reported open-market purchase or sale of Viking Therapeutics common stock, nor any price paid or received. The filing was signed on Chen’s behalf by Michael Morneau as attorney-in-fact on June 3, 2026. While the economic size of the award cannot be determined from the provided text, the reported action matters because equity option grants and vesting schedules are a common form of executive or insider compensation, tying potential future value to Viking Therapeutics’ stock performance and potentially affecting insider beneficial ownership over time.